Larbex® Steri-Neb (Budesonide)

Budesonide binds to glucocorticoid receptors inside cells, creating a complex that enters the nucleus and modifies gene expression. This down‑regulates pro‑inflammatory cytokines, limits leukocyte migration, and stabilises vascular membranes, resulting in decreased inflammatory activity in the airways and gastrointestinal tract.

The exact dose of Larbex® Steri‑Neb is set by the prescribing healthcare professional based on the patient’s age, severity of disease, prior response to therapy, and any concomitant medications. Dosage adjustments are made during follow‑up visits to achieve optimal control while minimising side effects.

The safety of budesonide in pregnancy and lactation has not been definitively established. Healthcare providers should weigh the potential benefits against possible risks and discuss alternative options. Women who are pregnant, planning pregnancy, or breastfeeding should consult their physician before starting therapy.

To request Larbex® Steri‑Neb, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Larbex® Steri‑Neb delivers budesonide, a high‑potency inhaled corticosteroid with extensive first‑pass metabolism, which limits systemic exposure compared with some alternatives. Its pharmacokinetic profile offers effective local anti‑inflammatory action while reducing the risk of systemic side effects, making it a competitive option among inhaled steroids for asthma and COPD.

Larbex® Steri‑Neb should be stored at ambient temperature, below 25 °C, in its original packaging. The container should be kept away from moisture, direct sunlight and heat sources to preserve drug stability and potency throughout its shelf life.

The product is administered by inhalation using the supplied device, typically a metered‑dose inhaler or nebuliser, as directed by the prescriber. Patients are often advised to use a spacer and to rinse the mouth after each dose to reduce local side effects such as oral thrush.

Serious risks include adrenal suppression, which can lead to cortisol deficiency, and an increased susceptibility to infections such as pneumonia. Rarely, severe allergic reactions like anaphylaxis may occur. Patients should report symptoms such as unexplained fatigue, severe shortness of breath, or swelling of the face and throat immediately.

Larbex® Steri‑Neb is contraindicated in individuals with known hypersensitivity to budesonide or any component of the formulation. It should also be avoided in patients with active, untreated systemic fungal, bacterial, viral, or parasitic infections until the infection is adequately managed.